Finance Watch: Four New VC Funds Provide $1.3bn For Biotech Start-Ups

Four Venture Mega-Rounds Total $844.5m

Private Company Edition: Newpath Partners’ second fund totals $350m, Merck KGaA committed €600m to M Ventures, Eir Ventures raised €122.3m and Breakout Ventures has $112.5m. Recent financings were led by SOTIO ($317.5m), Odyssey ($218m), Avistone ($200m) and Acepodia ($109m).

Biopharmaceutical companies and other life science start-ups may access $1.28bn in new venture capital available through four different sources, including Eir Venture Partners AB’s €122.3m ($138.1m) fund Eir Venture I AB and Breakout Ventures’ $112.5m Fund II, both announced on 9 December. Newpath Partners unveiled its second fund, which totals $350m, on 8 December – the same day Merck KGaA said it will add €600m ($680.5m) to its corporate VC fund M Ventures over the next five years.

Eir Ventures, a Nordic life science venture capital manager based in Stockholm and Copenhagen, launched its first VC fund in 2020 and recently closed Eir Ventures I AB. The fund...